The Centenary Institute is an independent leader in medical research seeking improved treatments and cures for cancer, cardiovascular and infectious diseases.
They are working to discover new prevention, early diagnosis and treatment options to enable each generation to live longer, healthier lives than the one before. Centenary’s affiliation with the RPA Hospital and the University of Sydney means that their discoveries can be quickly applied to the fight against disease in the clinic.
More at: www.centenary.org.auand www.centenarynews.org.au
$25,000 Centenary Institute Lawrence Creative Prize goes to young Melbourne researcher
One of Australia’s most creative young medical researchers has won a $25,000 prize to help her develop her ideas on how diet could prevent stroke deaths.
Connie Wong thinks we may be able to prevent early deaths following stroke with a fibre-based diet. She initially used innovative microscope techniques to determine how stroke weakens the immune system. Now she is studying how it also induces leakiness in the gut wall, leading to infection and an upsurge in deaths. And the solution may well lie in diet.
Centenary Institute Lawrence Creative Prize to be announced, finalists from Melbourne and Sydney
The winner of the Centenary Institute Lawrence Creative Prize will be announced at 6.30 pm, Tuesday 12 November 2013, at a reception hosted by UBS in Sydney.
There are three finalists. On Tuesday we will find out who is the overall winner of the $25,000 prize. The two runners-up will each receive $5,000.
Centenary’s discoveries lead to a commercial agreement to create drugs to fix leaking blood vessels
Australian molecular biologists led by researchers at Centenary have made a synthetic compound that appears to allow them to control the leakiness of blood vessels. The work could lead to effective new drug treatments for strokes and tumours. Spinoffs may include an ability to reduce the side-effects of chemotherapy and inflammation.
Their lead drug candidate, known as CD5-2, was developed with the assistance of Mirrx Therapeutics, a privately owned Danish biotechnology company. Today Centenary has signed an agreement to develop this and other potential drugs with Mirrx. The agreement was facilitated by Bio-Link Australia Pty Ltd.
Ramaciotti invests $1 million in a new approach to understanding human disease
“We’ll be able to ask individual immune cells where they’ve been and who they’ve been talking to…”
The University of Sydney and The Centenary Institute will establish the Ramaciotti Centre for Human Systems Biology in 2014 following the announcement earlier this evening of the $1 million Ramaciotti Biomedical Research Award.
‘The Holst effect’ opens up new therapeutic options for prostate cancer treatment.
24 September 2013
A team of researchers from Sydney, Vancouver, Adelaide and Brisbane are getting closer to a new treatment for prostate cancer that relies on starving tumours of essential nutrients they need to grow.
In work just published in the Journal of the National Cancer Institute, Dr Jeff Holst, from Sydney’s Centenary Institute and his colleagues have shown they can slow the growth of the cancer by blocking the proteins which pump the amino acid leucine into tumour cells.
Applications are now open for the $25,000 Centenary Institute Lawrence Creative Prize for early-career biomedical researchers.
We’re looking for early-career scientists in biomedical research with a uniquely creative way of significantly contributing to their chosen field. [continue reading…]
Researchers from the Gene and Stem Cell Therapy Program at Sydney’s Centenary Institute have confirmed that, far from being “junk”, the 97 per cent of human DNA that does not encode instructions for making proteins can play a significant role in controlling cell development.
And in doing so, the researchers have unravelled a previously unknown mechanism for regulating the activity of genes, increasing our understanding of the way cells develop and opening the way to new possibilities for therapy.
Australian liver disease specialists available for World Hepatitis Day interviews
Exciting early indications of a cure for Hepatitis C do not mean we should become complacent about the risks of contracting the debilitating disease, a leading Australian researcher warns.
Professor Geoff McCaughan, head of the Liver Immunobiology Program at Sydney’s Centenary Research Institute, says preliminary results of a newly developed oral treatment regime for liver transplant patients with Hepatitis C were showing promising results.
Sydney society unites to support Centenary
Tanya Plibersek, Richard Champion de Crespigny, Justice Margaret Beazley, Tom Wenkart and many other Sydney luminaries will join Centenary Foundation chairman Joseph Carrozzi, a managing partner of global accountants PricewaterhouseCoopers, at the 2013 Foundation Dinner this Friday, 31 March.
They’ll have the opportunity to bid for: Chairman box seats at ANZ Stadium for the Bledisloe Cup; their own private jazz performance by the Jonathan Zwartz Trio; five luxury nights in Tasmania to experience Hobart, the Bay of Fires and the innovative Museum of Old and New Art; or the work of some of Australia’s finest artists.
Sydney researchers have discovered a new type of immune cell in skin that plays a role in fighting off parasitic invaders such as ticks, mites, and worms, and could be linked to eczema and allergic skin diseases.
The team from the Immune Imaging and T cell Laboratories at the Centenary Institute worked with colleagues from SA Pathology in Adelaide, the Malaghan Institute in Wellington, New Zealand and the USA.